ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,533.86
-0.37%
Dow Jones
44,565.07
0.00%
Gold vs US Dollar
2,778.005
0.79%
Brent Oil
78.135
1.04%
Bitcoin
105,503.46
1.48%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Tevogen Bio Holdings Inc (TVGN)

  7. Tevogen Bio Holdings Inc (TVGN) News

Tevogen Bio (TVGN)

Tevogen Bio Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TVGN
DateTimeSourceHeadlineSymbolCompany
24/01/202500:53GlobeNewswire Inc.Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare ConferenceNASDAQ:TVGNTevogen Bio Holdings Inc
26/12/202417:21GlobeNewswire Inc.Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare ConferenceNASDAQ:TVGNTevogen Bio Holdings Inc
23/12/202414:38GlobeNewswire Inc.Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TVGNTevogen Bio Holdings Inc
19/12/202413:30GlobeNewswire Inc.Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth AgendaNASDAQ:TVGNTevogen Bio Holdings Inc
17/12/202418:32GlobeNewswire Inc.Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TVGNTevogen Bio Holdings Inc
10/12/202420:13GlobeNewswire Inc.Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TVGNTevogen Bio Holdings Inc
05/12/202416:03GlobeNewswire Inc.Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of FameNASDAQ:TVGNTevogen Bio Holdings Inc
26/11/202413:05GlobeNewswire Inc.Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth StrategyNASDAQ:TVGNTevogen Bio Holdings Inc
21/11/202420:59GlobeNewswire Inc.Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company ValueNASDAQ:TVGNTevogen Bio Holdings Inc
19/11/202421:50GlobeNewswire Inc.Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business ModelNASDAQ:TVGNTevogen Bio Holdings Inc
14/11/202422:00GlobeNewswire Inc.UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly FinancialsNASDAQ:TVGNTevogen Bio Holdings Inc
14/11/202420:49GlobeNewswire Inc.Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly FinancialsNASDAQ:TVGNTevogen Bio Holdings Inc
08/11/202420:36GlobeNewswire Inc.Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued OperationsNASDAQ:TVGNTevogen Bio Holdings Inc
05/11/202421:43GlobeNewswire Inc.Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient AffordabilityNASDAQ:TVGNTevogen Bio Holdings Inc
05/11/202414:27GlobeNewswire Inc.Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920NASDAQ:TVGNTevogen Bio Holdings Inc
04/11/202419:36GlobeNewswire Inc.Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient SupportNASDAQ:TVGNTevogen Bio Holdings Inc
31/10/202414:54GlobeNewswire Inc.Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing CostsNASDAQ:TVGNTevogen Bio Holdings Inc
29/10/202419:28GlobeNewswire Inc.Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the CompanyNASDAQ:TVGNTevogen Bio Holdings Inc
29/10/202416:43GlobeNewswire Inc.Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder EquityNASDAQ:TVGNTevogen Bio Holdings Inc
25/10/202421:34GlobeNewswire Inc.Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic AreasNASDAQ:TVGNTevogen Bio Holdings Inc
23/10/202412:35GlobeNewswire Inc.Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug DevelopmentNASDAQ:TVGNTevogen Bio Holdings Inc
22/10/202418:30GlobeNewswire Inc.Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This WeekNASDAQ:TVGNTevogen Bio Holdings Inc
21/10/202419:58GlobeNewswire Inc.Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 BillionNASDAQ:TVGNTevogen Bio Holdings Inc
21/10/202417:56GlobeNewswire Inc.Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming DaysNASDAQ:TVGNTevogen Bio Holdings Inc
19/10/202402:46GlobeNewswire Inc.Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming DaysNASDAQ:TVGNTevogen Bio Holdings Inc
17/10/202413:32GlobeNewswire Inc.Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to FollowNASDAQ:TVGNTevogen Bio Holdings Inc
17/10/202411:54GlobeNewswire Inc.Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 BillionNASDAQ:TVGNTevogen Bio Holdings Inc
16/10/202420:30GlobeNewswire Inc.Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health InequalityNASDAQ:TVGNTevogen Bio Holdings Inc
15/10/202418:30GlobeNewswire Inc.Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical LesionsNASDAQ:TVGNTevogen Bio Holdings Inc
15/10/202415:36GlobeNewswire Inc.Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for ImmeNASDAQ:TVGNTevogen Bio Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:TVGN

Your Recent History

BIT
S29284
Societe Generale Effekten
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads